Cassava Sciences (SAVA)

• Market cap: $110M
• 1 day: -2.98%
• 5 days: 7.55%
• 1 month: 7.55%
• 3 months: -29.85%
• 6 months: -1.3%
• Year to date: 9.09%
• 1 year: -12.31%
• 5 years: -95.45%
• 10 years: -82.3%
• Sector: Healthcare
• Industry: Biotechnology

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Employees: 30